TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Sisram Medical Ltd. ( (HK:1696) ) is now available.
Sisram Medical Ltd announced its interim results for the first half of 2025, reporting a slight decline in revenue by 1.9% to US$165.5 million compared to the same period in 2024. Despite this, the APAC region showed strong performance with a 17.6% increase in revenue, and the injectables line saw a significant growth of 218.1%. However, the company’s gross profit margin decreased by 2.4 percentage points, and adjusted net profit fell by 28.1%. The board decided not to declare an interim dividend for this period.
The most recent analyst rating on (HK:1696) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
More about Sisram Medical Ltd.
Sisram Medical Ltd, incorporated in Israel, operates in the medical industry, focusing on providing advanced medical solutions. The company is known for its injectables line and has a significant market presence in the APAC region.
Average Trading Volume: 1,530,315
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.67B
For a thorough assessment of 1696 stock, go to TipRanks’ Stock Analysis page.